头孢哌酮/舒巴坦体外抗菌活性的研究

中国临床药理学与治疗学 ›› 1996, Vol. 1 ›› Issue (1): 8-12.

头孢哌酮/舒巴坦体外抗菌活性的研究

方向群, 刘又宁, 王睿¹, 陈迁¹, 李勇¹, 陈孟莉¹, 赵志坚¹

解放军总医院呼吸科,¹临床药理研究室,北京 100853

收稿日期:1996-04-07 出版日期:1996-03-26 发布日期:2020-12-03
作者简介:方向群,男,29岁,医学硕士,主要从事抗菌药物的基础和临床研究

Study on the antibacterial activity in vitro of cefoperazone/sulbactam

Fang Xiangqun, Liu Youning, Wang Rui, Chen Qian, Li Yong, Che Mengli, Zhao Zhijian

Dept. of Pulmonary Medicine, Dept. of Clinical Pharmacology, Chinese PLA General Hospital, Beijing 100853

Received:1996-04-07 Online:1996-03-26 Published:2020-12-03

摘要/Abstract

摘要： 目的研究头咆哌酮单用,及与舒巴坦联用在体外的抗菌活性。方法采用琼脂平板稀释法测定头孢哌酮/舒巴坦(SPZ,比例1:1)、头孢哌酮(CPZ)和舒巴坦(SBT)对8种322株临床常见致病菌的最低抑菌浓度(MIC),并统计MIC₅₀、MIC₉₀ 、IC₅₀等数值。结果除金黄色葡萄球菌外,SPZ对其它7种致病菌的抗菌活性均强于CPZ,MIC₉₀值均下降2~4倍;SPZ对肺炎链球菌、流感嗜血杆菌的MIC₅₀值较CPZ有极大的降低;SPZ对53.2%的肠菌科细菌和40.7%的绿脓假单胞菌的MIC值有2倍以上的降低,9.04%的肠杆菌科细菌和33.3%的绿脓假单胞菌对CPZ耐药,52.9 %和50.0 %的CPZ耐药菌对SPZ敏感。SBT虽对受试菌均无明显抗菌活性,但其可能通过对β-内酰胺酶的抑制作用,提高了CPZ的抗菌活性。结论 SPZ可适用于CPZ耐药菌引起的严重感染。

关键词: 头孢哌酮, 舒巴坦, 最低抑菌浓度

Abstract: Aim To study the antibacterial activity in vitro of cefoperazone/ sulbactam. Methods The MIC₅₀, MIC₉₀ and IC₅₀ of cefoperazone (CPZ), sulbactam (SBT) sulperazone(SPZ) (a combina- tion of CPZ and SBT in a ratio of 1: 1) against 322 strains isolated clinically were determined and analyzed. Results SPZ was more effective than CPZ against the isolates except S. aureus. MIC₉₀ of SPZ to these isolates were reduced to 2 ~ to 4 - fold. MIC₅₀ of SPZ to S. pncumonia and Ⅱ. influenza were reduced remarkly; MICs of SPZ to 53.2 % strains of the family Enter-obacteriaceae and to 40.7 % strains of Ps. auruginosa reduced 2 - fold or more than CPZ. Tolerance to CPZ occurred in 9.04 % strains of the family enterobacteriaceae and in 33.3 % strains of Ps. auruginos and 52.9 % of the fomer and 50.0 % of the latter of CPZ resistant strains were susceptible to SPZ. Although there was almost no antibaterial activity of SBT against the isolates tested, but SBT may enhance the effectivity of CPZ,it may be induced by its inhibitory effect to β-lactamase. Conclusion SPZ may be used in treatment of serious infection caused by CPZ resistant isolates.

Key words: Sulperazone(SPZ), Minimun inhibitory concentration(MIC)

中图分类号:

R978.11

方向群, 刘又宁, 王睿, 陈迁, 李勇, 陈孟莉, 赵志坚. 头孢哌酮/舒巴坦体外抗菌活性的研究[J]. 中国临床药理学与治疗学, 1996, 1(1): 8-12.

Fang Xiangqun, Liu Youning, Wang Rui, Chen Qian, Li Yong, Che Mengli, Zhao Zhijian. Study on the antibacterial activity in vitro of cefoperazone/sulbactam[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(1): 8-12.

[1]	郑燕华, 陈峪, 顾磊. 美罗培南与头孢哌酮钠/舒巴坦钠治疗急性白血病合并重症肺部感染的疗效观察[J]. 中国临床药理学与治疗学, 2014, 19(3): 309-312.
[2]	黄瀚, 刘世坤. 对抗菌药物防突变浓度及突变选择窗两概念的探讨与思索[J]. 中国临床药理学与治疗学, 2008, 13(1): 21-24.
[3]	王进, 肖永红, 吕媛, 康子胜, 张明, 梁军, 刘燕, 张曼, 李天云. 注射用头孢曲松钠/舒巴坦钠健康人体连续给药耐受性及药代动力学研究[J]. 中国临床药理学与治疗学, 2006, 11(4): 458-463.
[4]	任少华, 胡华成. 抗菌药物药效学研究的若干进展[J]. 中国临床药理学与治疗学, 2002, 7(1): 86-89.
[5]	梁玉霞, 陈迁, 王睿, 方翼, 刘庆锋. 6种β^-内酰胺类抗生素对G^-杆菌的PAE 特点[J]. 中国临床药理学与治疗学, 1997, 2(3): 186-189.
[6]	王睿, 陈迁, 陈孟莉, 楼方定, 朱军, 韩晓苹, 谭次娥, 裴保香, 王爱珍. 头孢噻肟在恶性血液病合并感染患者体内杀菌效价及临床疗效比较[J]. 中国临床药理学与治疗学, 1997, 2(1): 17-19.
[7]	刘皈阳, 王睿, 方翼, 陈迁, 刘庆峰, 周亮, 秦延兵. 舒巴克坦对头孢哌酮体外抗生素后效应的影响[J]. 中国临床药理学与治疗学, 1997, 2(1): 20-22.